Literature DB >> 11118379

Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies.

M D Yeager1, M Aste-Amezaga, D R Brown, M M Martin, M J Shah, J C Cook, N D Christensen, C Ackerson, R S Lowe, J F Smith, P Keller, K U Jansen.   

Abstract

The development of vaccines against human papillomaviruses (HPVs) has long been hampered by the inability to grow HPVs in tissue culture and the lack of an efficient neutralization assay. To date, less than 10% of more than 100 different HPV types can be grown in athymic and "SCID" mouse xenograft systems or raft culture systems. Recently, the in vitro generation of HPV pseudovirions and their use in neutralization assays were demonstrated. The major shortcomings of the current approaches to HPV neutralization are the lack of HPV virions for most types for the xenograft methods and the time-consuming and inefficient generation of infective pseudovirions for the latter methods, which precludes their use in large-scale HPV clinical trials or epidemiological studies. We describe here a novel and efficient approach to generating pseudovirions in which HPV virus-like particles (VLPs) are coupled to the beta-lactamase gene as a reporter. We show that it is not necessary to encapsidate the reporter gene constructs into the pseudovirions. Using sera from human volunteers immunized with HPV-11 VLPs expressed in yeast, we demonstrate that our novel neutralization assay compares favorably with the athymic mouse neutralization assay. Furthermore, our assay was used to define neutralizing monoclonal antibodies to HPV-6, which were previously unknown. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11118379     DOI: 10.1006/viro.2000.0674

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  20 in total

1.  Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection.

Authors:  R B Roden; P M Day; B K Bronzo; W H Yutzy; Y Yang; D R Lowy; J T Schiller
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

2.  Development of bead-based immunoassay to quantify neutralizing antibody for human papillomavirus 16 and 18.

Authors:  Hai-Bo Liu; Pankaj Kumar Chaturvedi; Gantumur Battogtokh; Hyo Joo Bang; In-Wook Kim; Yong-Wan Kim; Kye-Shin Park; Woong Shick Ahn
Journal:  Mol Biotechnol       Date:  2013-06       Impact factor: 2.695

Review 3.  Proteoglycans in host-pathogen interactions: molecular mechanisms and therapeutic implications.

Authors:  Allison H Bartlett; Pyong Woo Park
Journal:  Expert Rev Mol Med       Date:  2010-02-01       Impact factor: 5.600

4.  Saccharomyces cerevisiae is permissive for replication of bovine papillomavirus type 1.

Authors:  Kong-Nan Zhao; Ian H Frazer
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

5.  Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions.

Authors:  Latifa Bousarghin; Alba-Lucia Combita-Rojas; Antoine Touzé; Slimane El Mehdaoui; Pierre-Yves Sizaret; Maria-Mercedes Bravo; Pierre Coursaget
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

6.  Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination.

Authors:  Hui Zhao; Zhi-Jie Lin; Shou-Jie Huang; Juan Li; Xiao-Hui Liu; Meng Guo; Jun Zhang; Ning-Shao Xia; Hui-Rong Pan; Ting Wu; Chang-Gui Li
Journal:  Hum Vaccin Immunother       Date:  2014-01-02       Impact factor: 3.452

7.  Generation and characterization of neutralizing monoclonal antibodies against baculo-expressed HPV 16 VLPs.

Authors:  P Vidyasagar; V N Sridevi; S Rajan; A Praveen; A Srikanth; G Abhinay; V Siva Kumar; R R Verma; L Rajendra
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2014-03-14

8.  Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.

Authors:  Peter Ohlschläger; Wolfram Osen; Kerstin Dell; Stefan Faath; Robert L Garcea; Ingrid Jochmus; Martin Müller; Michael Pawlita; Klaus Schäfer; Peter Sehr; Caroline Staib; Gerd Sutter; Lutz Gissmann
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

9.  The use of human papillomavirus seroepidemiology to inform vaccine policy.

Authors:  Mark Schiffman; Mahboobeh Safaeian; Nicolas Wentzensen
Journal:  Sex Transm Dis       Date:  2009-11       Impact factor: 2.830

10.  Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses.

Authors:  Alba-Lucia Combita; Antoine Touzé; Latifa Bousarghin; Neil D Christensen; Pierre Coursaget
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.